Vertex's Kalydeco for cystic fibrosis granted expanded use by Health Canada
Zerbor/iStock via Getty Images                 

Health Canada has expanded the indication for Vertex Pharmaceuticals' (NASDAQ:VRTX) cystic fibrosis medication Kalydeco (ivacaftor) in patients from 4 months to 18 years of age with a certain gene mutation.
The expansion applies to those in the age group with the R117HÂ mutation in the cystic fibrosis transmembrane conductance regulator ("CFTR") gene.
Earlier this week, Vertex (VRTX) was called a top large-cap biotech pick by Jefferies.